Advanced Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major advanced pancreatic cancer markets are expected to exhibit a CAGR of 5.79% during 2024-2034.
The advanced pancreatic cancer market has been comprehensively analyzed in IMARC's new report titled "Advanced Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Advanced pancreatic cancer refers to a stage IV tumor where the disease spreads (metastasized) to distant organs or tissues, such as the liver, lungs, abdominal cavity, or lymph nodes. It is a serious condition with a low survival rate. The common symptoms of the illness include abdominal or back pain, yellowing of the skin and eyes, unexplained weight loss, lack of appetite, nausea, vomiting, diarrhea, oily stools, fatigue, depression, mood changes, pain, redness, or swelling in the affected region, etc. In some cases, individuals suffering from this ailment may develop diabetes or experience a sudden change in blood sugar levels. The diagnosis of advanced pancreatic cancer typically involves a combination of medical history evaluation, clinical feature review, and a physical examination. Various imaging techniques, such as endoscopic ultrasound, positron emission tomography scans, magnetic resonance imaging, etc., are also used to detect the extent of cancer by showing areas with increased metabolic activity. The healthcare provider may further perform a biopsy to confirm the diagnosis of the disease and determine its characteristics.
The increasing cases of genetic disorders, which can lead to multiple variations in DNA mismatch repair genes, eventually resulting in uncontrolled cell growth, are primarily driving the advanced pancreatic cancer market. In addition to this, the rising prevalence of numerous risk factors, including smoking, advancing age, obesity, chronic pancreatitis, excessive alcohol consumption, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of immunotherapy drugs, like pembrolizumab and nivolumab, to stimulate the body's defense mechanism against cancerous cells is further bolstering the market growth. Apart from this, the inflating application of radiofrequency ablation procedures to treat the ailment owing to their several advantages, such as preserving pancreatic function, enhancing the overall treatment response, and improving outcomes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive trans-arterial chemoembolization techniques, which work by blocking the blood vessels connected to the tumor, to combat the spread of cancer in patients, is expected to drive the advanced pancreatic cancer market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the advanced pancreatic cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for advanced pancreatic cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the advanced pancreatic cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period:2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the advanced pancreatic cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the advanced pancreatic cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current advanced pancreatic cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the advanced pancreatic cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the advanced pancreatic cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the advanced pancreatic cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of advanced pancreatic cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced pancreatic cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced pancreatic cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with advanced pancreatic cancer across the seven major markets?
What is the size of the advanced pancreatic cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of advanced pancreatic cancer?
What will be the growth rate of patients across the seven major markets?
Advanced Pancreatic Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for advanced pancreatic cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the advanced pancreatic cancer market?
What are the key regulatory events related to the advanced pancreatic cancer market?
What is the structure of clinical trial landscape by status related to the advanced pancreatic cancer market?
What is the structure of clinical trial landscape by phase related to the advanced pancreatic cancer market?
What is the structure of clinical trial landscape by route of administration related to the advanced pancreatic cancer market?
The advanced pancreatic cancer market has been comprehensively analyzed in IMARC's new report titled "Advanced Pancreatic Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Advanced pancreatic cancer refers to a stage IV tumor where the disease spreads (metastasized) to distant organs or tissues, such as the liver, lungs, abdominal cavity, or lymph nodes. It is a serious condition with a low survival rate. The common symptoms of the illness include abdominal or back pain, yellowing of the skin and eyes, unexplained weight loss, lack of appetite, nausea, vomiting, diarrhea, oily stools, fatigue, depression, mood changes, pain, redness, or swelling in the affected region, etc. In some cases, individuals suffering from this ailment may develop diabetes or experience a sudden change in blood sugar levels. The diagnosis of advanced pancreatic cancer typically involves a combination of medical history evaluation, clinical feature review, and a physical examination. Various imaging techniques, such as endoscopic ultrasound, positron emission tomography scans, magnetic resonance imaging, etc., are also used to detect the extent of cancer by showing areas with increased metabolic activity. The healthcare provider may further perform a biopsy to confirm the diagnosis of the disease and determine its characteristics.
The increasing cases of genetic disorders, which can lead to multiple variations in DNA mismatch repair genes, eventually resulting in uncontrolled cell growth, are primarily driving the advanced pancreatic cancer market. In addition to this, the rising prevalence of numerous risk factors, including smoking, advancing age, obesity, chronic pancreatitis, excessive alcohol consumption, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of immunotherapy drugs, like pembrolizumab and nivolumab, to stimulate the body's defense mechanism against cancerous cells is further bolstering the market growth. Apart from this, the inflating application of radiofrequency ablation procedures to treat the ailment owing to their several advantages, such as preserving pancreatic function, enhancing the overall treatment response, and improving outcomes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive trans-arterial chemoembolization techniques, which work by blocking the blood vessels connected to the tumor, to combat the spread of cancer in patients, is expected to drive the advanced pancreatic cancer market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the advanced pancreatic cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for advanced pancreatic cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the advanced pancreatic cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period:2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the advanced pancreatic cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the advanced pancreatic cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current advanced pancreatic cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the advanced pancreatic cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the advanced pancreatic cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the advanced pancreatic cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of advanced pancreatic cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced pancreatic cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced pancreatic cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with advanced pancreatic cancer across the seven major markets?
What is the size of the advanced pancreatic cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of advanced pancreatic cancer?
What will be the growth rate of patients across the seven major markets?
Advanced Pancreatic Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for advanced pancreatic cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the advanced pancreatic cancer market?
What are the key regulatory events related to the advanced pancreatic cancer market?
What is the structure of clinical trial landscape by status related to the advanced pancreatic cancer market?
What is the structure of clinical trial landscape by phase related to the advanced pancreatic cancer market?
What is the structure of clinical trial landscape by route of administration related to the advanced pancreatic cancer market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADVANCED PANCREATIC CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADVANCED PANCREATIC CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADVANCED PANCREATIC CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADVANCED PANCREATIC CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADVANCED PANCREATIC CANCER - UNMET NEEDS
10 ADVANCED PANCREATIC CANCER - KEY ENDPOINTS OF TREATMENT
11 ADVANCED PANCREATIC CANCER - MARKETED PRODUCTS
11.1 List of Advanced Pancreatic Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Tarceva (Erlotinib) - Astellas Pharma/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADVANCED PANCREATIC CANCER - PIPELINE DRUGS
12.1 List of Advanced Pancreatic Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Gemcitabine - RenovoRx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AB680 - Arcus Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 HCW9218 - HCW Biologics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 EndoTAG-1 - Syncore Biotechnology
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 L-DOS47 - Helix BioPharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ADVANCED PANCREATIC CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADVANCED PANCREATIC CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADVANCED PANCREATIC CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Advanced Pancreatic Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Advanced Pancreatic Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Advanced Pancreatic Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Advanced Pancreatic Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Advanced Pancreatic Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Advanced Pancreatic Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Advanced Pancreatic Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Advanced Pancreatic Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
16 ADVANCED PANCREATIC CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADVANCED PANCREATIC CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADVANCED PANCREATIC CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADVANCED PANCREATIC CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADVANCED PANCREATIC CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADVANCED PANCREATIC CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADVANCED PANCREATIC CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADVANCED PANCREATIC CANCER - UNMET NEEDS
10 ADVANCED PANCREATIC CANCER - KEY ENDPOINTS OF TREATMENT
11 ADVANCED PANCREATIC CANCER - MARKETED PRODUCTS
11.1 List of Advanced Pancreatic Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Tarceva (Erlotinib) - Astellas Pharma/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ADVANCED PANCREATIC CANCER - PIPELINE DRUGS
12.1 List of Advanced Pancreatic Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Gemcitabine - RenovoRx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AB680 - Arcus Biosciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 HCW9218 - HCW Biologics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 EndoTAG-1 - Syncore Biotechnology
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 L-DOS47 - Helix BioPharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ADVANCED PANCREATIC CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADVANCED PANCREATIC CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADVANCED PANCREATIC CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Advanced Pancreatic Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Advanced Pancreatic Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Advanced Pancreatic Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Advanced Pancreatic Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Advanced Pancreatic Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Advanced Pancreatic Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Advanced Pancreatic Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Advanced Pancreatic Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Advanced Pancreatic Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Advanced Pancreatic Cancer - Access and Reimbursement Overview
16 ADVANCED PANCREATIC CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADVANCED PANCREATIC CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADVANCED PANCREATIC CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
